LB Pharmaceuticals Inc announced the appointment of Joseph M. Miller as its new Chief Financial Officer, effective September 2, 2026. Mr. Miller brings over two decades of experience in public and private biotech firms, most recently serving as CFO of Aurinia Pharmaceuticals Inc. His employment agreement includes an annual base salary of $530,000, a target bonus equal to 40% of his salary, and a grant of options to purchase 200,000 shares of common stock vesting over four years. The appointment coincides with the company's approach toward pivotal NOVA-2 clinical trial results for its lead candidate LB-102 and preparations for potential commercialization in schizophrenia. LB Pharmaceuticals is a neuromedicines company developing therapies for underserved brain disorders.
